ENTITY
Roche Revisits Dyno for AAV Technology with $50M Upfront Payment
Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership
Pfizer Announces Additional Layoffs in North Carolina Following DMD Trial Setback
Pfizer layoffs, North Carolina, Duchenne muscular dystrophy (DMD), gene therapy trial failure, cost-cutting measures
Alpha-9 Radios Secures $175M Funding for RLT Portfolio Advancement
Alpha-9 radios, $175M funding, RLT portfolio, radiopharmaceuticals, biotech investment
Ocuphire Pharma Acquires Opus Genetics, Expanding into Inherited Retinal Disease Gene Therapies
Ocuphire Pharma, Opus Genetics, gene therapy, inherited retinal diseases (IRDs), merger, acquisition, biopharmaceutical, ophthalmic treatments
Alto Neuroscience’s Mid-Stage Depression Trial Fails, Casting Doubts on Neuropsychiatry R&D Strategy
Alto Neuroscience, depression trial, neuropsychiatry R&D, ALTO-100, biomarker strategy, clinical failure
NICE Rejects Alzheimer’s Drug Kisunla Despite UK Regulatory Approval
NICE, Alzheimer’s disease, donanemab, Kisunla, Eli Lilly, MHRA, NHS, cost-effectiveness
Pfizer Secures FDA Approval to Expand RSV Vaccine Abrysvo for High-Risk Adults Aged 18-59
Pfizer, RSV vaccine, Abrysvo, FDA approval, high-risk adults, immunocompromised adults
Merck Acquires “Chameleon” Approach to Combat Deadly Brain Cancers for $30 Million
Merck, brain cancer, chameleon approach, $30 million, pharmaceutical acquisition
Novo Nordisk Seeks FDA Ban on Compounded Semaglutide Formulations Amid Safety Concerns
Novo Nordisk, FDA, semaglutide, compounding pharmacies, safety concerns, GLP-1 medications, weight loss drugs, diabetes treatments
Sangamo Therapeutics Aligns with FDA on Accelerated Approval Pathway for ST-920 Gene Therapy in Fabry Disease
Sangamo Therapeutics, FDA, Accelerated Approval Pathway, ST-920, Fabry Disease, Gene Therapy, BLA Submission